Impact of Brain Cancer Care Coordinators on Healthcare Utilisation

By Melike Belenli Gümüş

July 22, 2024

Introduction

The Australian Institute of Health and Welfare reported a significant rise in cancer cases, with glioblastoma multiforme (GBM) accounting for 62% of all central nervous system cancers. GBM poses challenges due to its poor median survival rate of 14-16 months. The standard treatment protocol involves a multidisciplinary approach, emphasising the need for seamless coordination among various medical departments. Despite the existing protocols, the lack of a recognised standard regimen post-progression remains a concern.

Cancer care coordination plays a significant role in enhancing healthcare quality for patients, caregivers, and clinicians. Studies have highlighted the positive impact of patient navigators or cancer care coordinators on access to care, therapy adherence, and overall patient satisfaction. In a recent study, the impact of brain cancer care coordinators (BCCCs) on quantitative outcomes such as health service resource utilisation and survival rates of GBM patients was explored.

Role of Brain Cancer Care Coordinators

BCCCs are specialised nurses who support all patients diagnosed with primary brain cancers. They assist with navigation, symptom management, and emotional support for both patients and carers, providing help both in-person at hospitals and via phone calls. Their primary goal is to ensure that patients receive timely and appropriate care, reducing unnecessary hospital visits and improving overall outcomes.

An analysis was conducted on 187 patients diagnosed with glioblastoma within the Hunter New England Local Health District between 2013 and 2019. Healthcare utilisation and outcomes before and after the implementation of BCCCs were compared. The introduction of BCCCs in 2016 marked a significant change in patient management in terms of emergency department (ED) presentations, hospital admissions and the quality of patients’ lives.

ED Presentations and Hospital Admissions

One of the key findings of the study was the impact of BCCCs on ED presentations and hospital admissions. A noticeable reduction in ED visits, from 401 to 300, was observed after the introduction of BCCCs to the healthcare system. Consequently, the total length of stay in the hospital decreased by 25%. These reductions in healthcare resource utilisation underscore the efficiency and cost-effectiveness of BCCCs in managing GBM patients.

Overall Survival Rates

Hong et al. also examined overall survival rates among patients. Before the introduction of BCCCs, the median overall survival was 12.0 months. After the implementation of BCCCs, the median survival slightly decreased to 11.16 months. Although the difference in survival rates was not statistically significant, the reduction in time spent by patients in hospital and ED can be considered as an improvement in the patients’ quality of life.

Cost-Offset Analysis

The cost-offset analysis compared the investment in BCCCs against the valuation of healthcare resource use differences between the pre and post cohorts. The study found that the introduction of BCCCs led to a reduction in emergency presentations by AUD$1200 and hospital admissions by AUD$5500 per patient, which in turn result in an annual saving of AUD$167 634 in healthcare expenditures. When the cost of hiring the care coordinator was taken into account, the program demonstrates an annual net saving of AUD$4410. This finding supports the economic viability of investing in BCCCs as a means to improve patient care and reduce overall healthcare expenditure.

Figure 1: Costs per patient.

Conclusion

Analysing the data of glioblastoma patients allowed a comprehensive evaluation of the impact of cancer care coordinators as it is a disease with a well-established treatment protocol. BCCCs showed an important role in managing healthcare utilisation and outcomes for patients with glioblastoma. It was demonstrated that the introduction of BCCCs led to a reduction in ED presentations and hospital admissions. Although the impact on overall survival rates was not significant, the cost-offset analysis highlighted the economic benefits of investing in BCCCs.

As healthcare systems continue to evolve, the role of specialised care coordinators will become increasingly important. By providing targeted support and improving care coordination, BCCCs can enhance patient outcomes and reduce healthcare costs. Future research should focus on identifying the factors that influence survival rates and exploring ways to optimise the role of BCCCs in patient care.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.